Redeye was hoping for a bit more in terms of topline, but market demand has been hesitant, particula...
* Return to growth in Q3 driven by both M&A and organic recovery * Enedo headwinds should be more th...
* '25e-'27e adj. EBITA up 12-5% * Encouraging efficiency improvements and strategic initiatives * Tr...
Redeye updates its estimates and valuation after Relais’ Q3 2025 report.
Flexion has entered into a partnership with Xsolla, a global U.
Redeye provides a preview of its estimates ahead of BICO’s Q3 results, scheduled for release on Nove...
Relais Q3 adjusted EBITA of EUR 10.9m was up 19% y/y and came 5% below LSEG Data & Analytics consens...
* '25e-'27e sales cut by 20-14% on sluggish market and delayed orders * Rights issue of ~SEK 87m ann...
Redeye provides its initial take on Relais’ Q3 2025 report, which featured an adjusted EBITA that al...
Q3 report on Thursday, 23 October at 12:00 CET* '25e-'27e adj.
Redeye has updated its estimates following Physitrack’s Q3 2025 report, which was broadly in line wi...
Ependion’s Q3 report reflects a continued hesitant market and a flattish topline.
Redeye updates its estimates and valuation after Indutrade’s Q3 2025 report.
Redeye leaves a short comment on Xspray following today's news that the FDA has accepted its NDA for...
* Acquires NetApp partner Consular for DKK 65m, adds 3% to sales, 7% to EBITA * 4.
Finnair reports Q3 results on Oct 30. In our view the underlying Q3 results could already be relativ...
Redeye sees a Q3 report from Physitrack largely in line with our expectations.
Redeye sees a solid report from Lime. While the numbers were slightly below our expectations, the ye...
Redeye provides an update following Q-linea’s Q3 2025 report.
Redeye lowers its forecast following softer-than-expected Q3’25 figures.
